CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 223 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05562687
NCT05562687N/ACompleted

Investigation of Association Between Single Nucleotide Polymorphisms in Genes of the Apelin/ APJ System (-1860T>C & G212A) and CAD Risk and Hypertension in Syrian Patients

Damascus University·observational·Posted Oct 3, 2022·Updated Apr 1, 2026

In Brief

An observational study for Coronary Artery Disease and Hypertension. Completed, enrolled 223 participants across 1 site.

Detailed Summary

The apelin-APJ signaling pathway has emerged as an important novel mediator of cardiovascular control and blood pressure homeostasis. Genetic variation in apelin and its receptors likely contributes to essential hypertension, in addition to a range of traditional risk factors. Thus, a study will be conducted on Syrian patients with hypertension and coronary artery disease to investigate some of the single polymorphisms in the apelin gene and its receptor that may be responsible for the development of these diseases, and to link the levels of this peptide and its receptor in the blood with these polymorphisms and the percentage of these diseases (as shown by many Modern Global Reference Studies).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSyria
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 3, 2022
Enrollment StartDec 15, 2019
Primary CompletionJan 5, 2022
Study CompletionAug 18, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.7 years ago